Xenon Pharmaceuticals Inc.
XENE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.17 | -0.25 | 8.52 | -3.16 |
| FCF Yield | -2.26% | -2.61% | -2.34% | -1.80% |
| EV / EBITDA | -34.45 | -25.05 | -35.13 | -38.25 |
| Quality | ||||
| ROIC | -16.87% | -14.55% | -10.21% | -9.58% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 0.76 | 0.95 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,957,333.82% | 284.44% | 123.92% | -100.00% |
| Free Cash Flow Growth | -11.87% | -4.37% | -11.83% | -9.78% |
| Safety | ||||
| Net Debt / EBITDA | 1.07 | 1.35 | 1.50 | 1.74 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5.32 | -681.84 | 103.79 | 0.00 |